Skip to main content
OpenTrials
Completed

NCT Number: NCT02405455

Cerclage vs Cervical Pessary in Women With Cervical Incompetence

Cervical insufficiency (CI), responsible for 8% of preterm births (PB), is used to describe painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies. Structural weakness of cervical tissue was thought to cause or contribute to these adverse outcomes. The term has also been applied to women with one or two such losses/births or at risk for second-trimester pregnancy loss/birth. Cervical pessary and cervical cerclage are both considered as preventive treatments in women at risk for PB. This study aims to demonstrate that the cervical pessary could reduce the preterm birth rate before 37 weeks of gestation in women with prior PB due to cervical insufficiency or in women with prior PB and a short cervix in the current pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Methods/Design: This is an open-label, pilot, multicentre, prospective, randomised controlled trial (RCT). Enrolees are women with singleton pregnancies and previous PB based on CI (primary intervention, <16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, <24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment. The primary outcome is the spontaneous preterm birth rate before 34 weeks of gestation. The sample size was calculated, as a pilot study, based on the estimated population that we will be able to recruit during the duration of the trial: 60 women, 30 for each group (cervical cerclage and cervical pessary group) to observe, at least a reduction in the PB rate < 34 weeks from 34% to 27% in the pessary group, as does cerclage.

Discussion: The outcome of this study will show the effectiveness of a cervical cerclage and of a cervical pessary in this group of patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy
  • Minimum age: 18 years
  • Previous PB based on CI (primary intervention, <16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, <24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment.

Exclusion criteria

  • Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
  • Threatened preterm labour at time of randomization
  • Spontaneous rupture of membranes at time of randomization
  • Chorioamnionitis at time of randomization
  • Active vaginal bleeding
  • Placenta previa

Treatment and study plan

Cerclage

Procedure

Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.

Cervical pessary

Device

The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.

Primary outcomes

  1. Spontaneous delivery before 34 complete weeks

    Time frame: Before 34 weeks of gestation

    Spontaneous delivery before 34 complete weeks

Secondary outcomes

  1. Spontaneous delivery before 28 complete weeks

    Time frame: Before 28 weeks of gestation

    Spontaneous delivery before 28 complete weeks

  2. Spontaneous delivery before 37 complete weeks

    Time frame: Before 37 weeks of gestation

    Spontaneous delivery before 37 complete weeks

  3. Foetal and neonatal death

    Time frame: During pregnancy and during the first 28 days of newborn or NICU stay

    Foetal and neonatal death

  4. Neonatal morbidity

    Time frame: 28 days of newborn or during NICU stay

    Neonatal morbidity

  5. Maternal side effects

    Time frame: During pregnancy

    Maternal side effects

  6. Maternal morbidity

    Time frame: during pregnancy

    Maternal morbidity

  7. Number of participants with chorioamnionitis infection

    Time frame: During pregnancy

    Number of participants with chorioamnionitis infection

  8. Hospitalisation for threatened preterm labour

    Time frame: During pregnancy

    Hospitalisation for threatened preterm labour

Sponsors and collaborators

Lead sponsor

Maternal-Infantil Vall d´Hebron Hospital

Other

Registry information

Acronym: CEPEIC

Important dates

Study start
2015
Primary completion
2021
Study completion
2021
First posted
Apr 1, 2015
Registry last updated
Mar 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.